- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05308264
Studio di R289 in pazienti con sindromi mielodisplastiche a basso rischio (LR MDS)
Uno studio di fase 1b in aperto su R289, un inibitore IRAK1/4, in pazienti con sindromi mielodisplastiche a basso rischio (LR MDS) che sono refrattari/resistenti a terapie precedenti
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
An open-label, Phase 1b study of R289, an IRAK 1/4 Inhibitor, to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed/refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), luspatercept, or hypomethylating agents (HMAs) for MDS.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Strait Hicklin
- Numero di telefono: (650) 624-1100
- Email: shicklin@rigel.com
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- University of California, Los Angeles
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- University of California, Irvine
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Stanford Cancer Institute
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- WashU Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Oncology Clinical Research Referral Office
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Ichan School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Reclutamento
- Duke Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- Cleveland Clinic
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- University of Texas, Southwestern
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84009
- Reclutamento
- Intermountain Healthcare
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patient must be ≥ 18 years of age at the time of signing the informed consent.
-
Must have definitive diagnosis of MDS with very low, low, or intermediate-1 risk (International Prognostic Scoring System (IPSS)-R ≤ 3.5) and ≤5% bone marrow myeloblasts.
-
Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs(i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.
-
DOSE ESCALATION PHASE:
a. Must meet at least one of the following criteria prior to initial administration of study treatment: 1) Symptomatic anemia with hemoglobin < 9.0 g/dL and no RBC transfusion within 16 of registration or 2) RBC transfusion dependent defined as receiving ≥ 2 units of packed red blood cells (PRBCs) within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL.
-
DOSE EXPANSION PHASE:
- Relapsed, refractory to or ineligible for ESAs and has previously received one or more approved therapies for LR-MDS
- Must be RBC transfusion dependent defined as receiving ≥ 2 units of packed red blood cells (PRBCs) within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL.
-
EXPLORATORY PHASE 1b COHORT:
- Transfusion-dependent LR-MDS who are refractory or intolerant to, or are ineligible for ESAs.
- No prior therapy with any approved or investigational therapies for MDS
- No del 5q cytogenetic abnormality
- RBC transfusion dependent defined as receiving ≥ 2 units of PRBCs within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL
-
All patients must have documented marrow iron stores. If marrow iron stain is not available, the transferrin saturation must be >20% or a serum ferritin > 100ng/100mL
-
Must have Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 at screening.
-
Must have adequate organ function, defined as:
-
Hepatic function:
- aspartate amino transferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 × upper limit of normal (ULN)
- total bilirubin ≤ 1.5 × ULN
-
Renal function defined as creatinine clearance > 60 mL/min (using Cockcroft-Gault), or blood creatine < 1.5 mg/dL
-
Exclusion Criteria:
-
Prior treatment for MDS (i.e., TPOs, EPOs, luspatercept, HMAs) concluded < 4 weeks prior to study treatment
-
Clinically significant anemia resulting from iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis, or GI bleeding.
-
MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases.
-
Diagnosis of chronic myelomonocytic leukemia.
-
History of uncontrolled seizures.
-
Uncontrolled bacterial or viral infection (i.e., documented HIV, hepatitis B or hepatitis C).
-
History of other malignancy that could affect compliance or interpretation of results. Patients with an malignancy other than leukemia appropriately treated with curative intent and the malignancy has been in remission without treatment for ≥ 2 years prior to study entry are eligible as are:
- Adequately treated in situ carcinoma of the cervix uteri
- Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin, or
- Low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected.
-
History of or active, clinically significant, cardiovascular, respiratory, GI, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator's opinion (or following review by the Sponsor), could affect the conduct of the study or the absorption, metabolism or excretion of the study treatment.
-
Prior history of autologous or allogeneic stem cell transplantation
-
Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 480 milliseconds [msec]) (Common Terminology Criteria for Adverse Events [CTCAE] Grade 1) using Fridericia's QT correction formula.
-
History of additional risk factors for TdP (e.g., symptomatic heart failure with left ventricular ejection fraction [LVEF] <40%, hypokalemia, family history of Long QT Syndrome).
-
Receiving any other concurrent chemotherapy, radiotherapy, or immunotherapy (within 2 weeks of initiating study treatment), or the toxicity of the relevant prior treatment has not been resolved yet. For any long-acting systemic agent such as a monoclonal antibody, study treatment should not begin within two half-lives of the agent.
-
Use of concomitant medications that prolong the QT/QTc interval during study treatment
-
Use of concomitant medications that are strong CYP3A or CYP2B6 inhibitors or inducers during study treatment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental
ESCALATION PHASE: Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd Dose Level 4: 250 mg PO bid Dose Level 5: 500 mg PO AM/250 mg PO PM Dose Level 6: 500 mg PO bid EXPANSION PHASE (randomized 1:1): Dose Level 1: 500 mg PO qd Dose Level 2: 500 mg PO bid |
Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and Tolerability
Lasso di tempo: 2 Year
|
|
2 Year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Outcome Measure: Preliminary Efficacy
Lasso di tempo: 24 Weeks for Primary Efficacy; 8 Weeks for Characterized PK
|
Measure Description Primary Efficacy: Proportion of patients achieving red blood cell transfusions independence by ≥ 8 weeks, ≥ 16 weeks, and ≥ 24 weeks Proportion of patients with overall response per IWG 2006 Proportion of patients with hematologic improvement per IWG 2018 Time Frame: 24 Weeks Measure Description Characterized PK Maximum plasma concentration (Cmax) Time Frame: 8 Weeks |
24 Weeks for Primary Efficacy; 8 Weeks for Characterized PK
|
|
Characterize pharmacokinetics (PK)
Lasso di tempo: 8 Weeks
|
Maximum plasma concentration (Cmax) |
8 Weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Characterize pharmacodynamic (PD)
Lasso di tempo: 1 year
|
Change from baseline biomarker expression levels in plasma and bone marrow (including but not limited to, C-reactive protein [CRP] and tumor necrosis factor [TNF]-a) |
1 year
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- C-906289-002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .